APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

GLP-1 Diabetes Treatment Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global GLP-1 Diabetes Treatment Drugs Market Outlook and Growth Opportunities 2026

23 December 2025191 pages

Choose your research edition.

Industry ResearchGLP-1 Diabetes Treatment Drugs Industry Research Report 2026133 pages · $2,950 USDIndustry Growth & TrendsGlobal GLP-1 Diabetes Treatment Drugs Industry Growth and Trends Forecast to 2032113 pages · $3,450 USDMarket StructureGlobal GLP-1 Diabetes Treatment Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal GLP-1 Diabetes Treatment Drugs Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal GLP-1 Diabetes Treatment Drugs Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global GLP-1 Diabetes Treatment Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for GLP-1 Diabetes Treatment Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for GLP-1 Diabetes Treatment Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for GLP-1 Diabetes Treatment Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the GLP-1 Diabetes Treatment Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the GLP-1 Diabetes Treatment Drugs market include Tonghua Dongbao, Shanghai Renhui Biopharmaceuticals Co., Ltd., Sanofi, Page Biopharmaceuticals, Novo Nordisk, Eli Lilly, Jiangsu Hausen Pharmaceuticals Group Co., Ltd., Huadong Medicine and Ganli Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global GLP-1 Diabetes Treatment Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of GLP-1 Diabetes Treatment Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents GLP-1 Diabetes Treatment Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the GLP-1 Diabetes Treatment Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

GLP-1 Diabetes Treatment Drugs Segment by Company

Tonghua Dongbao

Shanghai Renhui Biopharmaceuticals Co., Ltd.

Sanofi

Page Biopharmaceuticals

Novo Nordisk

Eli Lilly

Jiangsu Hausen Pharmaceuticals Group Co., Ltd.

Huadong Medicine

Ganli Pharmaceuticals

AstraZeneca

Teva Pharmaceutical Industries Ltd

Pfizer Inc

Hanmi Pharmaceutical Co

GlaxoSmithKline (GSK)

Boehringer Ingelheim

GLP-1 Diabetes Treatment Drugs Segment by Type

Exenatide

Dulaglutide

Laglutide

Others

GLP-1 Diabetes Treatment Drugs Segment by Application

Online Pharmacy

Hospital

Clinic

GLP-1 Diabetes Treatment Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global GLP-1 Diabetes Treatment Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions GLP-1 Diabetes Treatment Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify GLP-1 Diabetes Treatment Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze GLP-1 Diabetes Treatment Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global GLP-1 Diabetes Treatment Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of GLP-1 Diabetes Treatment Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of GLP-1 Diabetes Treatment Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the GLP-1 Diabetes Treatment Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global GLP-1 Diabetes Treatment Drugs industry.

Chapter 3: Detailed analysis of GLP-1 Diabetes Treatment Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of GLP-1 Diabetes Treatment Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of GLP-1 Diabetes Treatment Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. GLP-1 Diabetes Treatment Drugs Industry Trends Table 2. GLP-1 Diabetes Treatment Drugs Industry Drivers Table 3. GLP-1 Diabetes Treatment Drugs Industry Opportunities and Challenges Table 4. GLP-1 Diabetes Treatment Drugs Industry Restraints Table 5. Global GLP-1 Diabetes Treatment Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global GLP-1 Diabetes Treatment Drugs Revenue Share by Company (2021-2026) Table 7. Global GLP-1 Diabetes Treatment Drugs Sales Volume by Company (k units) & (2021-2026) Table 8. Global GLP-1 Diabetes Treatment Drugs Sales Volume Share by Company (2021-2026) Table 9. Global GLP-1 Diabetes Treatment Drugs Average Price (USD/unit) of Company (2021-2026) Table 10. Global GLP-1 Diabetes Treatment Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global GLP-1 Diabetes Treatment Drugs Key Company Manufacturing Base & Headquarters Table 12. Global GLP-1 Diabetes Treatment Drugs Company, Product Type & Application Table 13. Global GLP-1 Diabetes Treatment Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global GLP-1 Diabetes Treatment Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Exenatide Table 18. Significant Companies of Dulaglutide Table 19. Significant Companies of Laglutide Table 20. Significant Companies of Others Table 21. Global GLP-1 Diabetes Treatment Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 22. Global GLP-1 Diabetes Treatment Drugs Sales Volume by Type (2021-2026) & (k units) Table 23. Global GLP-1 Diabetes Treatment Drugs Sales Volume by Type (2027-2032) & (k units) Table 24. Global GLP-1 Diabetes Treatment Drugs Sales Volume Share by Type (2021-2026) Table 25. Global GLP-1 Diabetes Treatment Drugs Sales Volume Share by Type (2027-2032) Table 26. Global GLP-1 Diabetes Treatment Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global GLP-1 Diabetes Treatment Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global GLP-1 Diabetes Treatment Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global GLP-1 Diabetes Treatment Drugs Sales Value Share by Type (2021-2026) Table 30. Global GLP-1 Diabetes Treatment Drugs Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Online Pharmacy Table 32. Significant Companies of Hospital Table 33. Significant Companies of Clinic Table 34. Global GLP-1 Diabetes Treatment Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 35. Global GLP-1 Diabetes Treatment Drugs Sales Volume by Application (2021-2026) & (k units) Table 36. Global GLP-1 Diabetes Treatment Drugs Sales Volume by Application (2027-2032) & (k units) Table 37. Global GLP-1 Diabetes Treatment Drugs Sales Volume Share by Application (2021-2026) Table 38. Global GLP-1 Diabetes Treatment Drugs Sales Volume Share by Application (2027-2032) Table 39. Global GLP-1 Diabetes Treatment Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global GLP-1 Diabetes Treatment Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global GLP-1 Diabetes Treatment Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global GLP-1 Diabetes Treatment Drugs Sales Value Share by Application (2021-2026) Table 43. Global GLP-1 Diabetes Treatment Drugs Sales Value Share by Application (2027-2032) Table 44. Global GLP-1 Diabetes Treatment Drugs Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 45. Global GLP-1 Diabetes Treatment Drugs Sales by Region (2021-2026) & (k units) Table 46. Global GLP-1 Diabetes Treatment Drugs Sales Market Share by Region (2021-2026) Table 47. Global GLP-1 Diabetes Treatment Drugs Sales by Region (2027-2032) & (k units) Table 48. Global GLP-1 Diabetes Treatment Drugs Sales Market Share by Region (2027-2032) Table 49. Global GLP-1 Diabetes Treatment Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global GLP-1 Diabetes Treatment Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global GLP-1 Diabetes Treatment Drugs Sales Value Share by Region (2021-2026) Table 52. Global GLP-1 Diabetes Treatment Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global GLP-1 Diabetes Treatment Drugs Sales Value Share by Region (2027-2032) Table 54. Global GLP-1 Diabetes Treatment Drugs Market Average Price (USD/unit) by Region (2021-2026) Table 55. Global GLP-1 Diabetes Treatment Drugs Market Average Price (USD/unit) by Region (2027-2032) Table 56. Global GLP-1 Diabetes Treatment Drugs Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 57. Global GLP-1 Diabetes Treatment Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global GLP-1 Diabetes Treatment Drugs Sales by Country (2021-2026) & (k units) Table 59. Global GLP-1 Diabetes Treatment Drugs Sales Market Share by Country (2021-2026) Table 60. Global GLP-1 Diabetes Treatment Drugs Sales by Country (2027-2032) & (k units) Table 61. Global GLP-1 Diabetes Treatment Drugs Sales Market Share by Country (2027-2032) Table 62. Global GLP-1 Diabetes Treatment Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global GLP-1 Diabetes Treatment Drugs Sales Value Market Share by Country (2021-2026) Table 64. Global GLP-1 Diabetes Treatment Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global GLP-1 Diabetes Treatment Drugs Sales Value Market Share by Country (2027-2032) Table 66. Tonghua Dongbao Company Information Table 67. Tonghua Dongbao Business Overview Table 68. Tonghua Dongbao GLP-1 Diabetes Treatment Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 69. Tonghua Dongbao GLP-1 Diabetes Treatment Drugs Product Portfolio Table 70. Tonghua Dongbao Recent Development Table 71. Shanghai Renhui Biopharmaceuticals Co., Ltd. Company Information Table 72. Shanghai Renhui Biopharmaceuticals Co., Ltd. Business Overview Table 73. Shanghai Renhui Biopharmaceuticals Co., Ltd. GLP-1 Diabetes Treatment Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 74. Shanghai Renhui Biopharmaceuticals Co., Ltd. GLP-1 Diabetes Treatment Drugs Product Portfolio Table 75. Shanghai Renhui Biopharmaceuticals Co., Ltd. Recent Development Table 76. Sanofi Company Information Table 77. Sanofi Business Overview Table 78. Sanofi GLP-1 Diabetes Treatment Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 79. Sanofi GLP-1 Diabetes Treatment Drugs Product Portfolio Table 80. Sanofi Recent Development Table 81. Page Biopharmaceuticals Company Information Table 82. Page Biopharmaceuticals Business Overview Table 83. Page Biopharmaceuticals GLP-1 Diabetes Treatment Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 84. Page Biopharmaceuticals GLP-1 Diabetes Treatment Drugs Product Portfolio Table 85. Page Biopharmaceuticals Recent Development Table 86. Novo Nordisk Company Information Table 87. Novo Nordisk Business Overview Table 88. Novo Nordisk GLP-1 Diabetes Treatment Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 89. Novo Nordisk GLP-1 Diabetes Treatment Drugs Product Portfolio Table 90. Novo Nordisk Recent Development Table 91. Eli Lilly Company Information Table 92. Eli Lilly Business Overview Table 93. Eli Lilly GLP-1 Diabetes Treatment Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 94. Eli Lilly GLP-1 Diabetes Treatment Drugs Product Portfolio Table 95. Eli Lilly Recent Development Table 96. Jiangsu Hausen Pharmaceuticals Group Co., Ltd. Company Information Table 97. Jiangsu Hausen Pharmaceuticals Group Co., Ltd. Business Overview Table 98. Jiangsu Hausen Pharmaceuticals Group Co., Ltd. GLP-1 Diabetes Treatment Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 99. Jiangsu Hausen Pharmaceuticals Group Co., Ltd. GLP-1 Diabetes Treatment Drugs Product Portfolio Table 100. Jiangsu Hausen Pharmaceuticals Group Co., Ltd. Recent Development Table 101. Huadong Medicine Company Information Table 102. Huadong Medicine Business Overview Table 103. Huadong Medicine GLP-1 Diabetes Treatment Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 104. Huadong Medicine GLP-1 Diabetes Treatment Drugs Product Portfolio Table 105. Huadong Medicine Recent Development Table 106. Ganli Pharmaceuticals Company Information Table 107. Ganli Pharmaceuticals Business Overview Table 108. Ganli Pharmaceuticals GLP-1 Diabetes Treatment Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 109. Ganli Pharmaceuticals GLP-1 Diabetes Treatment Drugs Product Portfolio Table 110. Ganli Pharmaceuticals Recent Development Table 111. AstraZeneca Company Information Table 112. AstraZeneca Business Overview Table 113. AstraZeneca GLP-1 Diabetes Treatment Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 114. AstraZeneca GLP-1 Diabetes Treatment Drugs Product Portfolio Table 115. AstraZeneca Recent Development Table 116. Teva Pharmaceutical Industries Ltd Company Information Table 117. Teva Pharmaceutical Industries Ltd Business Overview Table 118. Teva Pharmaceutical Industries Ltd GLP-1 Diabetes Treatment Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 119. Teva Pharmaceutical Industries Ltd GLP-1 Diabetes Treatment Drugs Product Portfolio Table 120. Teva Pharmaceutical Industries Ltd Recent Development Table 121. Pfizer Inc Company Information Table 122. Pfizer Inc Business Overview Table 123. Pfizer Inc GLP-1 Diabetes Treatment Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 124. Pfizer Inc GLP-1 Diabetes Treatment Drugs Product Portfolio Table 125. Pfizer Inc Recent Development Table 126. Hanmi Pharmaceutical Co Company Information Table 127. Hanmi Pharmaceutical Co Business Overview Table 128. Hanmi Pharmaceutical Co GLP-1 Diabetes Treatment Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 129. Hanmi Pharmaceutical Co GLP-1 Diabetes Treatment Drugs Product Portfolio Table 130. Hanmi Pharmaceutical Co Recent Development Table 131. GlaxoSmithKline (GSK) Company Information Table 132. GlaxoSmithKline (GSK) Business Overview Table 133. GlaxoSmithKline (GSK) GLP-1 Diabetes Treatment Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 134. GlaxoSmithKline (GSK) GLP-1 Diabetes Treatment Drugs Product Portfolio Table 135. GlaxoSmithKline (GSK) Recent Development Table 136. Boehringer Ingelheim Company Information Table 137. Boehringer Ingelheim Business Overview Table 138. Boehringer Ingelheim GLP-1 Diabetes Treatment Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 139. Boehringer Ingelheim GLP-1 Diabetes Treatment Drugs Product Portfolio Table 140. Boehringer Ingelheim Recent Development Table 141. Key Raw Materials Table 142. Raw Materials Key Suppliers Table 143. GLP-1 Diabetes Treatment Drugs Distributors List Table 144. GLP-1 Diabetes Treatment Drugs Customers List Table 145. Research Programs/Design for This Report Table 146. Authors List of This Report Table 147. Secondary Sources Table 148. Primary Sources List of Figures Figure 1. GLP-1 Diabetes Treatment Drugs Product Image Figure 2. Global GLP-1 Diabetes Treatment Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global GLP-1 Diabetes Treatment Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global GLP-1 Diabetes Treatment Drugs Sales (2021-2032) & (k units) Figure 5. Global GLP-1 Diabetes Treatment Drugs Sales Average Price (USD/unit) & (2021-2032) Figure 6. Global GLP-1 Diabetes Treatment Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Exenatide Image Figure 10. Dulaglutide Image Figure 11. Laglutide Image Figure 12. Others Image Figure 13. Global GLP-1 Diabetes Treatment Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 14. Global GLP-1 Diabetes Treatment Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global GLP-1 Diabetes Treatment Drugs Sales Volume Share by Type (2021-2032) Figure 16. Global GLP-1 Diabetes Treatment Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global GLP-1 Diabetes Treatment Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global GLP-1 Diabetes Treatment Drugs Sales Value Share by Type (2021-2032) Figure 19. Online Pharmacy Image Figure 20. Hospital Image Figure 21. Clinic Image Figure 22. Global GLP-1 Diabetes Treatment Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 23. Global GLP-1 Diabetes Treatment Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global GLP-1 Diabetes Treatment Drugs Sales Volume Share by Application (2021-2032) Figure 25. Global GLP-1 Diabetes Treatment Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global GLP-1 Diabetes Treatment Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global GLP-1 Diabetes Treatment Drugs Sales Value Share by Application (2021-2032) Figure 28. Global GLP-1 Diabetes Treatment Drugs Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 29. Global GLP-1 Diabetes Treatment Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global GLP-1 Diabetes Treatment Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global GLP-1 Diabetes Treatment Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America GLP-1 Diabetes Treatment Drugs Sales Value (2021-2032) & (US$ Million) Figure 33. North America GLP-1 Diabetes Treatment Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe GLP-1 Diabetes Treatment Drugs Sales Value (2021-2032) & (US$ Million) Figure 35. Europe GLP-1 Diabetes Treatment Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific GLP-1 Diabetes Treatment Drugs Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific GLP-1 Diabetes Treatment Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America GLP-1 Diabetes Treatment Drugs Sales Value (2021-2032) & (US$ Million) Figure 39. South America GLP-1 Diabetes Treatment Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa GLP-1 Diabetes Treatment Drugs Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa GLP-1 Diabetes Treatment Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA GLP-1 Diabetes Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA GLP-1 Diabetes Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA GLP-1 Diabetes Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada GLP-1 Diabetes Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada GLP-1 Diabetes Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada GLP-1 Diabetes Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico GLP-1 Diabetes Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico GLP-1 Diabetes Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico GLP-1 Diabetes Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany GLP-1 Diabetes Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany GLP-1 Diabetes Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany GLP-1 Diabetes Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France GLP-1 Diabetes Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France GLP-1 Diabetes Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France GLP-1 Diabetes Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. GLP-1 Diabetes Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. GLP-1 Diabetes Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. GLP-1 Diabetes Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy GLP-1 Diabetes Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy GLP-1 Diabetes Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy GLP-1 Diabetes Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain GLP-1 Diabetes Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain GLP-1 Diabetes Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain GLP-1 Diabetes Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia GLP-1 Diabetes Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia GLP-1 Diabetes Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia GLP-1 Diabetes Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands GLP-1 Diabetes Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands GLP-1 Diabetes Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands GLP-1 Diabetes Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries GLP-1 Diabetes Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries GLP-1 Diabetes Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries GLP-1 Diabetes Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China GLP-1 Diabetes Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China GLP-1 Diabetes Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China GLP-1 Diabetes Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan GLP-1 Diabetes Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan GLP-1 Diabetes Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan GLP-1 Diabetes Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea GLP-1 Diabetes Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea GLP-1 Diabetes Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea GLP-1 Diabetes Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India GLP-1 Diabetes Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India GLP-1 Diabetes Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India GLP-1 Diabetes Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia GLP-1 Diabetes Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia GLP-1 Diabetes Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia GLP-1 Diabetes Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia GLP-1 Diabetes Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia GLP-1 Diabetes Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia GLP-1 Diabetes Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil GLP-1 Diabetes Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil GLP-1 Diabetes Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil GLP-1 Diabetes Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina GLP-1 Diabetes Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina GLP-1 Diabetes Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina GLP-1 Diabetes Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile GLP-1 Diabetes Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile GLP-1 Diabetes Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile GLP-1 Diabetes Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia GLP-1 Diabetes Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia GLP-1 Diabetes Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia GLP-1 Diabetes Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru GLP-1 Diabetes Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru GLP-1 Diabetes Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru GLP-1 Diabetes Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia GLP-1 Diabetes Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia GLP-1 Diabetes Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia GLP-1 Diabetes Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel GLP-1 Diabetes Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia GLP-1 Diabetes Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia GLP-1 Diabetes Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE GLP-1 Diabetes Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE GLP-1 Diabetes Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE GLP-1 Diabetes Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey GLP-1 Diabetes Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey GLP-1 Diabetes Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey GLP-1 Diabetes Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran GLP-1 Diabetes Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran GLP-1 Diabetes Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran GLP-1 Diabetes Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt GLP-1 Diabetes Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt GLP-1 Diabetes Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt GLP-1 Diabetes Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. GLP-1 Diabetes Treatment Drugs Value Chain Figure 127. Manufacturing Cost Structure Figure 128. GLP-1 Diabetes Treatment Drugs Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Exenatide
  • Dulaglutide
  • Laglutide
  • Others
Applications
  • Online Pharmacy
  • Hospital
  • Clinic
Companies covered
  • Tonghua Dongbao
  • Shanghai Renhui Biopharmaceuticals Co., Ltd.
  • Sanofi
  • Page Biopharmaceuticals
  • Novo Nordisk
  • Eli Lilly
  • Jiangsu Hausen Pharmaceuticals Group Co., Ltd.
  • Huadong Medicine
  • Ganli Pharmaceuticals
  • AstraZeneca
  • Teva Pharmaceutical Industries Ltd
  • Pfizer Inc
  • Hanmi Pharmaceutical Co
  • GlaxoSmithKline (GSK)
  • Boehringer Ingelheim

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global GLP-1 Diabetes Treatment Drugs Sales Value (2021-2032)
  4. 1.2.2 Global GLP-1 Diabetes Treatment Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global GLP-1 Diabetes Treatment Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 GLP-1 Diabetes Treatment Drugs Market Dynamics
  1. 2.1 GLP-1 Diabetes Treatment Drugs Industry Trends
  2. 2.2 GLP-1 Diabetes Treatment Drugs Industry Drivers
  3. 2.3 GLP-1 Diabetes Treatment Drugs Industry Opportunities and Challenges
  4. 2.4 GLP-1 Diabetes Treatment Drugs Industry Restraints
3 GLP-1 Diabetes Treatment Drugs Market by Company
  1. 3.1 Global GLP-1 Diabetes Treatment Drugs Company Revenue Ranking in 2025
  2. 3.2 Global GLP-1 Diabetes Treatment Drugs Revenue by Company (2021-2026)
  3. 3.3 Global GLP-1 Diabetes Treatment Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global GLP-1 Diabetes Treatment Drugs Average Price by Company (2021-2026)
  5. 3.5 Global GLP-1 Diabetes Treatment Drugs Company Ranking (2024-2026)
  6. 3.6 Global GLP-1 Diabetes Treatment Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global GLP-1 Diabetes Treatment Drugs Company Product Type and Application
  8. 3.8 Global GLP-1 Diabetes Treatment Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global GLP-1 Diabetes Treatment Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 GLP-1 Diabetes Treatment Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 GLP-1 Diabetes Treatment Drugs Market by Type
  1. 4.1 GLP-1 Diabetes Treatment Drugs Type Introduction
  2. 4.1.1 Exenatide
  3. 4.1.2 Dulaglutide
  4. 4.1.3 Laglutide
  5. 4.1.4 Others
  6. 4.2 Global GLP-1 Diabetes Treatment Drugs Sales Volume by Type
  7. 4.2.1 Global GLP-1 Diabetes Treatment Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global GLP-1 Diabetes Treatment Drugs Sales Volume by Type (2021-2032)
  9. 4.2.3 Global GLP-1 Diabetes Treatment Drugs Sales Volume Share by Type (2021-2032)
  10. 4.3 Global GLP-1 Diabetes Treatment Drugs Sales Value by Type
  11. 4.3.1 Global GLP-1 Diabetes Treatment Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global GLP-1 Diabetes Treatment Drugs Sales Value by Type (2021-2032)
  13. 4.3.3 Global GLP-1 Diabetes Treatment Drugs Sales Value Share by Type (2021-2032)
5 GLP-1 Diabetes Treatment Drugs Market by Application
  1. 5.1 GLP-1 Diabetes Treatment Drugs Application Introduction
  2. 5.1.1 Online Pharmacy
  3. 5.1.2 Hospital
  4. 5.1.3 Clinic
  5. 5.2 Global GLP-1 Diabetes Treatment Drugs Sales Volume by Application
  6. 5.2.1 Global GLP-1 Diabetes Treatment Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global GLP-1 Diabetes Treatment Drugs Sales Volume by Application (2021-2032)
  8. 5.2.3 Global GLP-1 Diabetes Treatment Drugs Sales Volume Share by Application (2021-2032)
  9. 5.3 Global GLP-1 Diabetes Treatment Drugs Sales Value by Application
  10. 5.3.1 Global GLP-1 Diabetes Treatment Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global GLP-1 Diabetes Treatment Drugs Sales Value by Application (2021-2032)
  12. 5.3.3 Global GLP-1 Diabetes Treatment Drugs Sales Value Share by Application (2021-2032)
6 GLP-1 Diabetes Treatment Drugs Regional Sales and Value Analysis
  1. 6.1 Global GLP-1 Diabetes Treatment Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global GLP-1 Diabetes Treatment Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global GLP-1 Diabetes Treatment Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global GLP-1 Diabetes Treatment Drugs Sales by Region (2027-2032)
  5. 6.3 Global GLP-1 Diabetes Treatment Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global GLP-1 Diabetes Treatment Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global GLP-1 Diabetes Treatment Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global GLP-1 Diabetes Treatment Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global GLP-1 Diabetes Treatment Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America GLP-1 Diabetes Treatment Drugs Sales Value (2021-2032)
  12. 6.6.2 North America GLP-1 Diabetes Treatment Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe GLP-1 Diabetes Treatment Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe GLP-1 Diabetes Treatment Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific GLP-1 Diabetes Treatment Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific GLP-1 Diabetes Treatment Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America GLP-1 Diabetes Treatment Drugs Sales Value (2021-2032)
  21. 6.9.2 South America GLP-1 Diabetes Treatment Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa GLP-1 Diabetes Treatment Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa GLP-1 Diabetes Treatment Drugs Sales Value Share by Country, 2025 VS 2032
7 GLP-1 Diabetes Treatment Drugs Country-level Sales and Value Analysis
  1. 7.1 Global GLP-1 Diabetes Treatment Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global GLP-1 Diabetes Treatment Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global GLP-1 Diabetes Treatment Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global GLP-1 Diabetes Treatment Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global GLP-1 Diabetes Treatment Drugs Sales by Country (2027-2032)
  6. 7.4 Global GLP-1 Diabetes Treatment Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global GLP-1 Diabetes Treatment Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global GLP-1 Diabetes Treatment Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA GLP-1 Diabetes Treatment Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA GLP-1 Diabetes Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA GLP-1 Diabetes Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada GLP-1 Diabetes Treatment Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada GLP-1 Diabetes Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada GLP-1 Diabetes Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico GLP-1 Diabetes Treatment Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico GLP-1 Diabetes Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico GLP-1 Diabetes Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany GLP-1 Diabetes Treatment Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany GLP-1 Diabetes Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany GLP-1 Diabetes Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France GLP-1 Diabetes Treatment Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France GLP-1 Diabetes Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France GLP-1 Diabetes Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. GLP-1 Diabetes Treatment Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. GLP-1 Diabetes Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. GLP-1 Diabetes Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy GLP-1 Diabetes Treatment Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy GLP-1 Diabetes Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy GLP-1 Diabetes Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain GLP-1 Diabetes Treatment Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain GLP-1 Diabetes Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain GLP-1 Diabetes Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia GLP-1 Diabetes Treatment Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia GLP-1 Diabetes Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia GLP-1 Diabetes Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands GLP-1 Diabetes Treatment Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands GLP-1 Diabetes Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands GLP-1 Diabetes Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries GLP-1 Diabetes Treatment Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries GLP-1 Diabetes Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries GLP-1 Diabetes Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China GLP-1 Diabetes Treatment Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China GLP-1 Diabetes Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China GLP-1 Diabetes Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan GLP-1 Diabetes Treatment Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan GLP-1 Diabetes Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan GLP-1 Diabetes Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea GLP-1 Diabetes Treatment Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea GLP-1 Diabetes Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea GLP-1 Diabetes Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India GLP-1 Diabetes Treatment Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India GLP-1 Diabetes Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India GLP-1 Diabetes Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia GLP-1 Diabetes Treatment Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia GLP-1 Diabetes Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia GLP-1 Diabetes Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia GLP-1 Diabetes Treatment Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia GLP-1 Diabetes Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia GLP-1 Diabetes Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil GLP-1 Diabetes Treatment Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil GLP-1 Diabetes Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil GLP-1 Diabetes Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina GLP-1 Diabetes Treatment Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina GLP-1 Diabetes Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina GLP-1 Diabetes Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile GLP-1 Diabetes Treatment Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile GLP-1 Diabetes Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile GLP-1 Diabetes Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia GLP-1 Diabetes Treatment Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia GLP-1 Diabetes Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia GLP-1 Diabetes Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru GLP-1 Diabetes Treatment Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru GLP-1 Diabetes Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru GLP-1 Diabetes Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia GLP-1 Diabetes Treatment Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia GLP-1 Diabetes Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia GLP-1 Diabetes Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel GLP-1 Diabetes Treatment Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel GLP-1 Diabetes Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel GLP-1 Diabetes Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE GLP-1 Diabetes Treatment Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE GLP-1 Diabetes Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE GLP-1 Diabetes Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey GLP-1 Diabetes Treatment Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey GLP-1 Diabetes Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey GLP-1 Diabetes Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran GLP-1 Diabetes Treatment Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran GLP-1 Diabetes Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran GLP-1 Diabetes Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt GLP-1 Diabetes Treatment Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt GLP-1 Diabetes Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt GLP-1 Diabetes Treatment Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Tonghua Dongbao
  2. 8.1.1 Tonghua Dongbao Company Information
  3. 8.1.2 Tonghua Dongbao Business Overview
  4. 8.1.3 Tonghua Dongbao GLP-1 Diabetes Treatment Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Tonghua Dongbao GLP-1 Diabetes Treatment Drugs Product Portfolio
  6. 8.1.5 Tonghua Dongbao Recent Developments
  7. 8.2 Shanghai Renhui Biopharmaceuticals Co., Ltd.
  8. 8.2.1 Shanghai Renhui Biopharmaceuticals Co., Ltd. Company Information
  9. 8.2.2 Shanghai Renhui Biopharmaceuticals Co., Ltd. Business Overview
  10. 8.2.3 Shanghai Renhui Biopharmaceuticals Co., Ltd. GLP-1 Diabetes Treatment Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Shanghai Renhui Biopharmaceuticals Co., Ltd. GLP-1 Diabetes Treatment Drugs Product Portfolio
  12. 8.2.5 Shanghai Renhui Biopharmaceuticals Co., Ltd. Recent Developments
  13. 8.3 Sanofi
  14. 8.3.1 Sanofi Company Information
  15. 8.3.2 Sanofi Business Overview
  16. 8.3.3 Sanofi GLP-1 Diabetes Treatment Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Sanofi GLP-1 Diabetes Treatment Drugs Product Portfolio
  18. 8.3.5 Sanofi Recent Developments
  19. 8.4 Page Biopharmaceuticals
  20. 8.4.1 Page Biopharmaceuticals Company Information
  21. 8.4.2 Page Biopharmaceuticals Business Overview
  22. 8.4.3 Page Biopharmaceuticals GLP-1 Diabetes Treatment Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Page Biopharmaceuticals GLP-1 Diabetes Treatment Drugs Product Portfolio
  24. 8.4.5 Page Biopharmaceuticals Recent Developments
  25. 8.5 Novo Nordisk
  26. 8.5.1 Novo Nordisk Company Information
  27. 8.5.2 Novo Nordisk Business Overview
  28. 8.5.3 Novo Nordisk GLP-1 Diabetes Treatment Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Novo Nordisk GLP-1 Diabetes Treatment Drugs Product Portfolio
  30. 8.5.5 Novo Nordisk Recent Developments
  31. 8.6 Eli Lilly
  32. 8.6.1 Eli Lilly Company Information
  33. 8.6.2 Eli Lilly Business Overview
  34. 8.6.3 Eli Lilly GLP-1 Diabetes Treatment Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Eli Lilly GLP-1 Diabetes Treatment Drugs Product Portfolio
  36. 8.6.5 Eli Lilly Recent Developments
  37. 8.7 Jiangsu Hausen Pharmaceuticals Group Co., Ltd.
  38. 8.7.1 Jiangsu Hausen Pharmaceuticals Group Co., Ltd. Company Information
  39. 8.7.2 Jiangsu Hausen Pharmaceuticals Group Co., Ltd. Business Overview
  40. 8.7.3 Jiangsu Hausen Pharmaceuticals Group Co., Ltd. GLP-1 Diabetes Treatment Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Jiangsu Hausen Pharmaceuticals Group Co., Ltd. GLP-1 Diabetes Treatment Drugs Product Portfolio
  42. 8.7.5 Jiangsu Hausen Pharmaceuticals Group Co., Ltd. Recent Developments
  43. 8.8 Huadong Medicine
  44. 8.8.1 Huadong Medicine Company Information
  45. 8.8.2 Huadong Medicine Business Overview
  46. 8.8.3 Huadong Medicine GLP-1 Diabetes Treatment Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Huadong Medicine GLP-1 Diabetes Treatment Drugs Product Portfolio
  48. 8.8.5 Huadong Medicine Recent Developments
  49. 8.9 Ganli Pharmaceuticals
  50. 8.9.1 Ganli Pharmaceuticals Company Information
  51. 8.9.2 Ganli Pharmaceuticals Business Overview
  52. 8.9.3 Ganli Pharmaceuticals GLP-1 Diabetes Treatment Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Ganli Pharmaceuticals GLP-1 Diabetes Treatment Drugs Product Portfolio
  54. 8.9.5 Ganli Pharmaceuticals Recent Developments
  55. 8.10 AstraZeneca
  56. 8.10.1 AstraZeneca Company Information
  57. 8.10.2 AstraZeneca Business Overview
  58. 8.10.3 AstraZeneca GLP-1 Diabetes Treatment Drugs Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 AstraZeneca GLP-1 Diabetes Treatment Drugs Product Portfolio
  60. 8.10.5 AstraZeneca Recent Developments
  61. 8.11 Teva Pharmaceutical Industries Ltd
  62. 8.11.1 Teva Pharmaceutical Industries Ltd Company Information
  63. 8.11.2 Teva Pharmaceutical Industries Ltd Business Overview
  64. 8.11.3 Teva Pharmaceutical Industries Ltd GLP-1 Diabetes Treatment Drugs Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Teva Pharmaceutical Industries Ltd GLP-1 Diabetes Treatment Drugs Product Portfolio
  66. 8.11.5 Teva Pharmaceutical Industries Ltd Recent Developments
  67. 8.12 Pfizer Inc
  68. 8.12.1 Pfizer Inc Company Information
  69. 8.12.2 Pfizer Inc Business Overview
  70. 8.12.3 Pfizer Inc GLP-1 Diabetes Treatment Drugs Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Pfizer Inc GLP-1 Diabetes Treatment Drugs Product Portfolio
  72. 8.12.5 Pfizer Inc Recent Developments
  73. 8.13 Hanmi Pharmaceutical Co
  74. 8.13.1 Hanmi Pharmaceutical Co Company Information
  75. 8.13.2 Hanmi Pharmaceutical Co Business Overview
  76. 8.13.3 Hanmi Pharmaceutical Co GLP-1 Diabetes Treatment Drugs Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Hanmi Pharmaceutical Co GLP-1 Diabetes Treatment Drugs Product Portfolio
  78. 8.13.5 Hanmi Pharmaceutical Co Recent Developments
  79. 8.14 GlaxoSmithKline (GSK)
  80. 8.14.1 GlaxoSmithKline (GSK) Company Information
  81. 8.14.2 GlaxoSmithKline (GSK) Business Overview
  82. 8.14.3 GlaxoSmithKline (GSK) GLP-1 Diabetes Treatment Drugs Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 GlaxoSmithKline (GSK) GLP-1 Diabetes Treatment Drugs Product Portfolio
  84. 8.14.5 GlaxoSmithKline (GSK) Recent Developments
  85. 8.15 Boehringer Ingelheim
  86. 8.15.1 Boehringer Ingelheim Company Information
  87. 8.15.2 Boehringer Ingelheim Business Overview
  88. 8.15.3 Boehringer Ingelheim GLP-1 Diabetes Treatment Drugs Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Boehringer Ingelheim GLP-1 Diabetes Treatment Drugs Product Portfolio
  90. 8.15.5 Boehringer Ingelheim Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 GLP-1 Diabetes Treatment Drugs Value Chain Analysis
  2. 9.1.1 GLP-1 Diabetes Treatment Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 GLP-1 Diabetes Treatment Drugs Sales Mode & Process
  6. 9.2 GLP-1 Diabetes Treatment Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 GLP-1 Diabetes Treatment Drugs Distributors
  9. 9.2.3 GLP-1 Diabetes Treatment Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst